 Home > Active Ingredient News > Antitumor Therapy > Lung Cancer: Pembrolizumab+chemotherapy vs. atezolizumab+chemotherapy+/− Bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC): an indirect comparative analysis of matching adjustment

Lung Cancer: Pembrolizumab+chemotherapy vs. atezolizumab+chemotherapy+/− Bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC): an indirect comparative analysis of matching adjustment

 Last Update: 2021-08-02
 Source: Internet
 Author: User

Tags

immune system response

11 64 mm

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The standard treatment for advanced non-squamous non-small cell lung cancer (NSCLC) is immunotherapy combined with chemotherapy
.

However, there is currently no head-to-head study comparing which immune combination chemotherapy has better efficacy

The standard treatment for advanced non-squamous non-small cell lung cancer (NSCLC) is immunotherapy combined with chemotherapy

The main study patients were KEYNOTE-021 cohort G (KN021 G) (pembrolizumab + carboplatin + pemetrexed; N = 59) and KEYNOTE-189 (KN189) (pembrolizumab + pemetrexed + platinum; N = 410) , And IMpower 130 (atezolizumab + carboplatin + albumin-bound paclitaxel; N = 451) and IMpower 150 (atezolizumab + carboplatin + paclitaxel + bevacizumab; N = 356)
.

The baseline characteristics of the two groups were adjusted, and then the adjusted OS, PFS and objective response rate (ORR) were evaluated

After adjusting and matching the atezolizumab+ chemotherapy patients in IMpower 130, there were 428 patients in the Pembrolizumab+ chemotherapy group

Efficacy comparison 1

After adjustment and matching of atezolizumab+chemotherapy+bevacizumab patients in IMpower 150, there were 389 patients in the Pembrolizumab+chemotherapy group
.

The median PFS of pembrolizumab + chemotherapy versus atezolizumab + chemotherapy + bevacizumab was 22.

After adjustment and matching of atezolizumab+chemotherapy+bevacizumab patients in IMpower 150, there were 389 patients in the Pembrolizumab+chemotherapy group

Efficacy comparison 2

For ORR, the estimated risk ratio (95% CI) and risk difference (95% CI) of pembrolizumab + chemotherapy and atezolizumab + chemotherapy were 0.
9 (0.
8, 1.
1) and-3.
5% (-10.
0, 3.
1), respectively
.

The pembrolizumab + chemotherapy and atezolizumab + chemotherapy + bevacizumab groups were 0.

For ORR, the estimated risk ratio (95% CI) and risk difference (95% CI) of pembrolizumab + chemotherapy and atezolizumab + chemotherapy were 0.

In summary, studies have shown that pembrolizumab + chemotherapy can bring OS and PFS benefits compared with atezolizumab + chemotherapy, and it can bring PFS benefits compared with atezolizumab + chemotherapy + bevacizumab

Original source:

Halmos B, Burke T, Kalyvas C, et al.

Halmos B, Burke T, Kalyvas C, et al.
Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.
Lung Cancer.
2021 May;155:175 -182.
doi: 10.
1016/j.
lungcan.
2021.
03.
020.
Epub 2021 Mar 30.
PMID: 33839603.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.